7 months ago
SMMT
AnalystsBradley CaninoBradley Canino's Stock Forecasts
AnalystsBradley Canino
Sectors:
Analyst Ranking
Bottom 7%
#4537 out of 4870 analysts
Average Return
-7.39%
Win Rate
28%24 out of 87
Risk vs Reward
Poor
Good
Bradley Canino's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Summit Therapeutics IncSMMT | +441.18% | $3.74 | $20.24 | 2024-03-26 - 2025-03-25 | Strong Buy |
Summit Therapeutics IncSMMT | +179.07% | $8.84 | $24.67 | 2024-06-03 - 2025-05-01 | Strong Buy |
Merus NvMRUS | +147.91% | $21.10 | $52.31 | 2023-10-24 - 2024-10-23 | Strong Buy |
Nuvalent IncNUVL | +121.46% | $45.63 | $101.05 | 2023-09-27 - 2024-09-26 | Strong Buy |
Deciphera Pharmaceuticals IncDCPH | +113.43% | $11.99 | $25.59 | 2023-10-31 - 2024-06-10 | Strong Buy |
Bradley Canino Analyst Color
Get additional color on Bradley Canino's coverage of popular stocks
8 months ago
NUVL
8 months ago
SMMT
a year ago
MRUS
a year ago
CCCC
Bradley Canino's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Black Diamond Therapeutics IncBDTX | 5 | Strong Buy | $15.00 | +782.35% | Maintains | 2 months ago |
Alx Oncology Holdings IncALXO | 7 | Hold | $1.50 | +190.70% | Maintains | 2 months ago |
Relay Therapeutics IncRLAY | 5 | Strong Buy | $23.00 | +599.09% | Maintains | 2 months ago |
Arvinas IncARVN | 6 | Strong Buy | $51.00 | +605.39% | Maintains | 3 months ago |
Janux Therapeutics IncJANX | 2 | Strong Buy | $115.00 | +258.81% | Maintains | 5 months ago |
Affimed NvAFMD | 6 | Hold | $4.00 | +263.64% | Maintains | 6 months ago |
Syndax Pharmaceuticals IncSNDX | 5 | Strong Buy | $41.00 | +196.67% | Maintains | 7 months ago |
Kura Oncology IncKURA | 6 | Hold | $19.00 | +192.76% | Downgrades | 7 months ago |
Celcuity IncCELC | 4 | Strong Buy | $42.00 | +288.89% | Maintains | 7 months ago |
Summit Therapeutics IncSMMT | 4 | Strong Buy | $40.00 | +62.14% | Maintains | 7 months ago |
Nuvalent IncNUVL | 3 | Strong Buy | $135.00 | +77.10% | Maintains | 8 months ago |
Oric Pharmaceuticals IncORIC | 1 | Strong Buy | $20.00 | +259.07% | Initiates Coverage On | 8 months ago |
Pyxis Oncology IncPYXS | 1 | Strong Buy | $10.00 | +809.09% | Initiates Coverage On | 9 months ago |
Zentalis Pharmaceuticals IncZNTL | 17 | Strong Buy | $10.00 | +589.66% | Maintains | 10 months ago |
Merus NvMRUS | 7 | Strong Buy | $99.00 | +117.82% | Maintains | a year ago |
C4 Therapeutics IncCCCC | 4 | Strong Buy | $14.00 | +758.90% | Maintains | a year ago |
Cullinan Therapeutics IncCGEM | 1 | Strong Buy | $40.00 | N/A | Initiates Coverage On | a year ago |
Blueprint Medicines CorpBPMC | 6 | Strong Buy | $130.00 | N/A | Maintains | a year ago |
Kymera Therapeutics IncKYMR | 4 | Strong Buy | $55.00 | N/A | Maintains | a year ago |
Deciphera Pharmaceuticals IncDCPH | 6 | Strong Buy | $23.00 | N/A | Maintains | a year ago |
Theseus Pharmaceuticals IncTHRX | 1 | Strong Buy | $24.00 | N/A | Initiates Coverage On | 2 years ago |
Turning Point Therapeutics IncTPTX | 2 | Hold | $45.00 | N/A | Maintains | 3 years ago |
Mersana Therapeutics IncMRSN | 1 | Hold | $18.00 | N/A | Initiates Coverage On | 4 years ago |
Seagen IncSGEN | 1 | Hold | $145.00 | N/A | Initiates Coverage On | 4 years ago |
Zymeworks IncZYME | 1 | Buy | $55.00 | N/A | Initiates Coverage On | 4 years ago |
Epizyme IncEPZM | 1 | Buy | $13.00 | N/A | Initiates Coverage On | 4 years ago |
Exelixis IncEXEL | 1 | Buy | $30.00 | N/A | Initiates Coverage On | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.